Episode Details
Back to Episodes
Aclarion’s NOCISCAN Targets a Breakthrough in Diagnosing Chronic Back Pain | Aclarion (NASDAQ: ACON) | The Watchlist E31
Description
In this episode of The Watchlist, Aclarion (NASDAQ: ACON) CEO Brent Ness explains how the company’s NOCISCAN technology aims to transform the diagnosis of chronic low back pain by revealing biomarkers traditional imaging can’t detect. Listeners will hear why the pivotal CLARITY trial could catalyze U.S. reimbursement, how physicians are already using the technology, and where adoption is expected to grow over the next several years.
This episode covers:
• What makes NOCISCAN a potential breakthrough in back-pain diagnostics
• How MR spectroscopy identifies pain-related biomarkers
• Why the CLARITY trial is essential for physician behavior and payer decisions
• U.K. reimbursement traction and implications for U.S. scaling
• Aclarion’s roadmap for payer coverage and scan-volume growth
Website: https://www.aclarion.com
Disclaimer: This podcast is made in partnership with Aclarion. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.